Harpoon Therapeutics, Inc. - HARP STOCK NEWS

Harpoon Therapeutics (HARP) presented interim results from a Phase 1 clinical trial of HPN217 for relapsed/refractory multiple myeloma at the ASH Annual Meeting. The trial involved 62 patients and showed a 77% objective response rate at the highest doses (12 and 24 mg). Many patients experienced durable responses, with 86% remaining on treatment. Low-grade cytokine release syndrome occurred in 29% of patients, with no Grade 3 events reported. Ongoing dose optimization is in progress, and the management plans to discuss these results in a conference call on December 12, 2022.

Harpoon Therapeutics, a clinical-stage immunotherapy firm, will host a conference call on December 12, 2022, at 4:30 p.m. ET to discuss updated interim results from its Phase 1 HPN217 clinical program, presented at the 64th American Society of Hematology Annual Meeting. Interested parties can join via phone or through a webcast on Harpoon's investor relations website. The company focuses on developing innovative T cell engagers using proprietary technology to treat cancer and other diseases, with initiatives aimed at solid tumors and hematologic malignancies.

Harpoon Therapeutics (HARP) provided a strategic update, focusing on ongoing clinical programs HPN217, HPN328, and HPN601. Following a corporate restructuring, 45% of the workforce will be reduced to cut operating expenses, with current cash of $66.1 million expected to fund operations through 2023. Q3 2022 revenue increased to $13.6 million compared to $4.5 million last year, driven by R&D collaborations. However, R&D expenses rose to $21 million, contributing to a net loss of $11.6 million. Upcoming milestones include data presentations at ASH 2022 and continued patient enrollment for clinical trials.

Harpoon Therapeutics (HARP) announced updated interim results from its Phase 1 clinical trial of HPN217 targeting relapsed/refractory multiple myeloma, to be presented at the ASH Annual Meeting on December 11, 2022. The trial showcases clinical proof of concept for HPN217, utilizing the TriTAC platform to engage T cells against tumor cells.

The results will include safety, efficacy, and pharmacodynamic data from patients, specifically at higher dose levels, highlighting the potential of HPN217 in oncology therapeutics.

Harpoon Therapeutics announces the appointment of Dr. Luke Walker, M.D., as the new Chief Medical Officer, effective October 3, 2022. Dr. Walker, previously with Seagen, will spearhead clinical development efforts for the company’s innovative T cell engager platforms. His extensive background includes key leadership roles in oncology drug development, notably overseeing the approval process for TUKYSA. The company also granted Dr. Walker a stock option to purchase 305,000 shares at $1.08 per share, vesting over four years.

Harpoon Therapeutics has appointed Lauren Silvernail to its Board of Directors and as the Chairperson of its Audit Committee. Silvernail, an industry veteran with over 30 years of financial leadership experience in life sciences, previously served in significant roles at Evolus, Revance Therapeutics, and Allergan. CEO Julie Eastland expressed confidence in Silvernail's expertise to guide the company's clinical development and business strategy. Harpoon focuses on novel T cell engagers for cancer treatment, leveraging its proprietary platforms to enhance therapeutic efficacy.

Harpoon Therapeutics (NASDAQ: HARP) announced its participation in three investor conferences in September 2022. These include one-on-one meetings at Citi's 17th Annual BioPharma Conference on September 8, a corporate presentation at H.C. Wainwright's Global Investment Conference on September 12 at 11:30 a.m. ET, and a session at Baird’s 2022 Global Healthcare Conference on September 13 at 4:20 p.m. ET. Presentations will be accessible on Harpoon's website, along with archived replays.

Harpoon Therapeutics (HARP) presented positive interim results for HPN328 at the ASCO Annual Meeting, addressing neuroendocrine cancers with a favorable safety profile. Financially, Q2 2022 saw revenues increase to $8.3 million, attributed mainly to a Development Option Agreement with AbbVie. However, cash reserves declined to $90.2 million from $136.6 million, extending funding into H2 2023. R&D expenses rose to $20.7 million, while net loss was $17.4 million for the quarter. Leadership changes include the departure of CFO Georgia Erbez, who will assist as a consultant.

Harpoon Therapeutics (NASDAQ: HARP), a clinical-stage immunotherapy company, announced its participation in two investor conferences. The first is a panel discussion at the Wedbush PacGrow Healthcare Conference on August 9, 2022, at 2:20 p.m. ET, focusing on immuno-oncology. The second is a corporate presentation at the Canaccord Genuity 42nd Annual Growth Conference in Boston on August 10, 2022, at 12 p.m. ET. A live audio webcast of the Canaccord presentation will be available on the Harpoon website.